search
Back to results

Walnuts and Healthy Aging (WAHA)

Primary Purpose

Age Related Cognitive Decline, Age Related Macular Degeneration

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Walnuts
habitual diet
Sponsored by
Loma Linda University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Age Related Cognitive Decline focused on measuring walnuts, age related cognitive decline, age related macular degeneration, healthy elderly subjects

Eligibility Criteria

63 Years - 79 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 63 to 79 years old
  • healthy men and women
  • able to attend clinic at a study sites

Exclusion Criteria:

  • illiteracy or inability to understand the protocol
  • unable to undergo neurophysiological tests
  • morbid obesity (BMI greater than or equal to ≥ 40 kg/m2)
  • uncontrolled diabetes (HbA1c>85)
  • uncontrolled hypertension
  • prior cerebrovascular accident
  • any relevant psychiatric illness, including major depression
  • advanced cognitive deterioration, dementia
  • other neurodegenerative diseases (i.e. Parkinson's disease)
  • any chronic illness expected to shorten survival (heart, liver, cancer, etc)
  • bereavement in the first year of loss
  • bad dentures unless fixable dental prostheses are used
  • allergy to walnuts
  • customary us of fish oil or flaxseed oil supplements
  • eye related exclusion criteria

Sites / Locations

  • Loma Linda University, Department of Nutrition
  • Hospital Clinic, University of Barcelona

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Walnut group

Control group

Arm Description

This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.

This group will eat their habitual diet and refrain from eating walnuts.

Outcomes

Primary Outcome Measures

Changes from baseline in global cognitive composite score
The composite score will be calculated using the scores from the tests listed below. We will calculate the standardized scores of each test as the score of each participant minus the group mean and divide by its standard deviation. The composite score is the mean of the standardized scores. The 12 tests are: Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Complex Figure (ROCF), Semantic Fluency (Animals), Boston Naming Test (BNT), Visual Object and Space Perception Battery (VOSP), Block Design section from the Wechsler Adult Intelligence Scale (WAIS-III), Trail Making Test (TMT), FAS Word Fluency, Stroop Color Word Test, Symbol Digit Modalities Test (SMDT) Digit Span from the WAIS-III and Conners Continuous Performance Test (CPT-II).
Changes from baseline in macular degeneration
This will be assessed: by stereoscopic digitized color fundus images graded by International Classification System for Age-Related Maculopathy (score range. 0 to 4; the higher the score, the worse the condition); by optical coherence tomography (OCT) measurements of macular thickness (in µm); by optical coherence tomography (OCT) measurements of retinal nervous fiber layer thickness (in µm).

Secondary Outcome Measures

Change from baseline in brain cortical thickness
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mm2.
Change from baseline in voxel-based morphometry
Changes will be assessed by brain magnetic resonance imaging (MRI) using GM density maps on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is GM density.
Change from baseline in white matter hyperintensity volumes
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mL.
Change from baseline in perfusion arterial spin labeling
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is ml/100 g/min.
Changes from baseline in brain activation
Changes will be assessed by Functional MRI (fMRI) on a randomly selected subset of participants. Only in Barcelona center. There are no units of measure.

Full Information

First Posted
June 20, 2012
Last Updated
June 21, 2021
Sponsor
Loma Linda University
Collaborators
University of Barcelona, California Walnut Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT01634841
Brief Title
Walnuts and Healthy Aging
Acronym
WAHA
Official Title
Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Loma Linda University
Collaborators
University of Barcelona, California Walnut Commission

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This will be a systematic investigation of the role of walnuts in preventing or slowing age related cognitive decline and age related macular degeneration. 700 subjects will be recruited between 2 sites, Loma Linda University in California, USA and Hospital Clinic in Barcelona, Spain. Participants will be randomly assigned to either the walnut group or the control group for a 2 year intervention. Baseline and annual data will be collected and analyzed.
Detailed Description
Epidemiological studies suggest that nutrients such as n-3 polyunsaturated fatty acid, antioxidants and B-vitamins may protect against age related cognitive decline. Small human studies have shown beneficial effects of polyphenol rich foods on cognition and age related macular degeneration. Walnuts are a rich source of n-3 polyunsaturated fatty acid, alpha-linolenic acid, antioxidants, polyphenols and other bioactive compounds. A 2-year intervention will be conducted with healthy, elderly subjects to investigate the role of walnuts in preventing or slowing age related cognitive decline and age related macular degeneration. 350 subjects, age 63 to 79 years, will be recruited at each of 2 sites, Loma Linda University in California and Hospital Clinic in Barcelona. Participants will be randomly assigned to one of two groups: walnut group (habitual diet with 1 or 2 oz/d walnut supplement) or control group (habitual diet only). At baseline and yearly, cardiometabolic risk factors, red blood cell membrane fatty acids, urinary polyphenols and biomarkers of inflammation and oxidation will be measured. Eye exam, blood pressure and cognitive function tests will be measured at the beginning and end of 2 years. At the Barcelona site only, participants will be given a brain MRI and carotid ultrasound. Descriptive results will be reported as mean plus/minus standard deviation. Primary analysis will be carried out on the basis of groups as randomly assigned. Results will be presented as appropriate effect sizes with a measure of precision (95% CI). Analysis of covariates gender, age, educational status will be conducted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age Related Cognitive Decline, Age Related Macular Degeneration
Keywords
walnuts, age related cognitive decline, age related macular degeneration, healthy elderly subjects

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
708 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Walnut group
Arm Type
Active Comparator
Arm Description
This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
This group will eat their habitual diet and refrain from eating walnuts.
Intervention Type
Dietary Supplement
Intervention Name(s)
Walnuts
Intervention Description
30 to 60g (1 to 2 oz) per day of walnuts
Intervention Type
Other
Intervention Name(s)
habitual diet
Intervention Description
Dietary information will be provided
Primary Outcome Measure Information:
Title
Changes from baseline in global cognitive composite score
Description
The composite score will be calculated using the scores from the tests listed below. We will calculate the standardized scores of each test as the score of each participant minus the group mean and divide by its standard deviation. The composite score is the mean of the standardized scores. The 12 tests are: Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Complex Figure (ROCF), Semantic Fluency (Animals), Boston Naming Test (BNT), Visual Object and Space Perception Battery (VOSP), Block Design section from the Wechsler Adult Intelligence Scale (WAIS-III), Trail Making Test (TMT), FAS Word Fluency, Stroop Color Word Test, Symbol Digit Modalities Test (SMDT) Digit Span from the WAIS-III and Conners Continuous Performance Test (CPT-II).
Time Frame
2 years
Title
Changes from baseline in macular degeneration
Description
This will be assessed: by stereoscopic digitized color fundus images graded by International Classification System for Age-Related Maculopathy (score range. 0 to 4; the higher the score, the worse the condition); by optical coherence tomography (OCT) measurements of macular thickness (in µm); by optical coherence tomography (OCT) measurements of retinal nervous fiber layer thickness (in µm).
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Change from baseline in brain cortical thickness
Description
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mm2.
Time Frame
2 years
Title
Change from baseline in voxel-based morphometry
Description
Changes will be assessed by brain magnetic resonance imaging (MRI) using GM density maps on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is GM density.
Time Frame
2 years
Title
Change from baseline in white matter hyperintensity volumes
Description
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mL.
Time Frame
2 years
Title
Change from baseline in perfusion arterial spin labeling
Description
Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is ml/100 g/min.
Time Frame
2 years
Title
Changes from baseline in brain activation
Description
Changes will be assessed by Functional MRI (fMRI) on a randomly selected subset of participants. Only in Barcelona center. There are no units of measure.
Time Frame
2 years
Other Pre-specified Outcome Measures:
Title
Change in carotid Intima-media thickness (mm)
Description
Changes will be assessed by high-resolution ultrasound. Only in Barcelona center.
Time Frame
2 years
Title
Incidence of plaque presence in carotid artery (yes/no)
Description
Changes will be assessed by high-resolution ultrasound. Only in Barcelona center.
Time Frame
2 years
Title
Change in carotid atheroma plaque height (mm)
Description
Changes will be assessed by high-resolution ultrasound. Only in Barcelona center.
Time Frame
2 years
Title
Change in body mass index (kg/m2)
Description
BMI will be calculated as weight in kilograms divided by height in metres squared
Time Frame
2 years
Title
Change in waist circumference (cm)
Description
Waist circumference will be measured to the nearest 0.5 cm by using an anthropometric tape midway between the lowest rib and at the iliac crest at minimal respiration
Time Frame
2 years
Title
Change in total fat (g)
Description
Changes will be assessed by Dual-energy X-ray absorptiometry. Only in Barcelona center.
Time Frame
2 years
Title
Change in Total lean tissue (g)
Description
Changes will be assessed by Dual-energy X-ray absorptiometry. Only in Barcelona center.
Time Frame
2 years
Title
Change in fasting serum total cholesterol (mg/dL)
Description
Fasting serum total cholesterol will be measured by a standard enzymatic method
Time Frame
2 years
Title
Change in fasting serum LDL-cholesterol (mg/dL)
Description
Fasting serum LDL-cholesterol will be estimated by the Friedewald formula
Time Frame
2 years
Title
Change in fasting serum HDL-cholesterol (mg/dL)
Description
Fasting serum HDL-cholesterol will be measured by a precipitation technique
Time Frame
2 years
Title
Change in fasting serum triglycerides (mg/dL)
Description
Fasting triglycerides will be measured by a standard enzymatic method
Time Frame
2 years
Title
Change in serum brain-derived neurotrophic factor (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum soluble-Selectin (ng/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum soluble-intercellular Adhesion Molecule 1 (ng/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum soluble-vascular cell adhesion molecule 1 (ng/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum amyloid A (ng/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum granulocyte-macrophage colony-stimulating factor (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum interferon-gamma (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum interleukin-1beta (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum interleukin-6 (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years
Title
Change in serum tumor necrosis factor alpha (pg/mL)
Description
Assessed by ELISA
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
63 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 63 to 79 years old healthy men and women able to attend clinic at a study sites Exclusion Criteria: illiteracy or inability to understand the protocol unable to undergo neurophysiological tests morbid obesity (BMI greater than or equal to ≥ 40 kg/m2) uncontrolled diabetes (HbA1c>85) uncontrolled hypertension prior cerebrovascular accident any relevant psychiatric illness, including major depression advanced cognitive deterioration, dementia other neurodegenerative diseases (i.e. Parkinson's disease) any chronic illness expected to shorten survival (heart, liver, cancer, etc) bereavement in the first year of loss bad dentures unless fixable dental prostheses are used allergy to walnuts customary us of fish oil or flaxseed oil supplements eye related exclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joan Sabate, MD, DrPH
Organizational Affiliation
Chair, Department of Nutrition
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Emilio Ros, MD, PhD
Organizational Affiliation
Director Lipid Clinic, Endocrinology & Nutrition Service
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loma Linda University, Department of Nutrition
City
Loma Linda
State/Province
California
ZIP/Postal Code
92350
Country
United States
Facility Name
Hospital Clinic, University of Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
33903255
Citation
Nyberg L, Magnussen F, Lundquist A, Baare W, Bartres-Faz D, Bertram L, Boraxbekk CJ, Brandmaier AM, Drevon CA, Ebmeier K, Ghisletta P, Henson RN, Junque C, Kievit R, Kleemeyer M, Knights E, Kuhn S, Lindenberger U, Penninx BWJH, Pudas S, Sorensen O, Vaque-Alcazar L, Walhovd KB, Fjell AM. Educational attainment does not influence brain aging. Proc Natl Acad Sci U S A. 2021 May 4;118(18):e2101644118. doi: 10.1073/pnas.2101644118.
Results Reference
derived
PubMed Identifier
33236064
Citation
Fjell AM, Sorensen O, Amlien IK, Bartres-Faz D, Brandmaier AM, Buchmann N, Demuth I, Drevon CA, Duzel S, Ebmeier KP, Ghisletta P, Idland AV, Kietzmann TC, Kievit RA, Kuhn S, Lindenberger U, Magnussen F, Macia D, Mowinckel AM, Nyberg L, Sexton CE, Sole-Padulles C, Pudas S, Roe JM, Sederevicius D, Suri S, Vidal-Pineiro D, Wagner G, Watne LO, Westerhausen R, Zsoldos E, Walhovd KB. Poor Self-Reported Sleep is Related to Regional Cortical Thinning in Aging but not Memory Decline-Results From the Lifebrain Consortium. Cereb Cortex. 2021 Mar 5;31(4):1953-1969. doi: 10.1093/cercor/bhaa332.
Results Reference
derived
PubMed Identifier
33017652
Citation
Sorensen O, Brandmaier AM, Macia D, Ebmeier K, Ghisletta P, Kievit RA, Mowinckel AM, Walhovd KB, Westerhausen R, Fjell A. Meta-analysis of generalized additive models in neuroimaging studies. Neuroimage. 2021 Jan 1;224:117416. doi: 10.1016/j.neuroimage.2020.117416. Epub 2020 Oct 2.
Results Reference
derived
PubMed Identifier
32827219
Citation
Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020 Aug 21;8(8):CD011737. doi: 10.1002/14651858.CD011737.pub3.
Results Reference
derived
PubMed Identifier
32428300
Citation
Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020 May 19;5(5):CD011737. doi: 10.1002/14651858.CD011737.pub2.
Results Reference
derived
PubMed Identifier
31912155
Citation
Sala-Vila A, Valls-Pedret C, Rajaram S, Coll-Padros N, Cofan M, Serra-Mir M, Perez-Heras AM, Roth I, Freitas-Simoes TM, Domenech M, Calvo C, Lopez-Illamola A, Bitok E, Buxton NK, Huey L, Arechiga A, Oda K, Lee GJ, Corella D, Vaque-Alcazar L, Sala-Llonch R, Bartres-Faz D, Sabate J, Ros E. Effect of a 2-year diet intervention with walnuts on cognitive decline. The Walnuts And Healthy Aging (WAHA) study: a randomized controlled trial. Am J Clin Nutr. 2020 Mar 1;111(3):590-600. doi: 10.1093/ajcn/nqz328.
Results Reference
derived
PubMed Identifier
30962275
Citation
Bartres-Faz D, Gonzalez-Escamilla G, Vaque-Alcazar L, Abellaneda-Perez K, Valls-Pedret C, Ros E, Grothe MJ. Characterizing the Molecular Architecture of Cortical Regions Associated with High Educational Attainment in Older Individuals. J Neurosci. 2019 Jun 5;39(23):4566-4575. doi: 10.1523/JNEUROSCI.2370-18.2019. Epub 2019 Apr 8.
Results Reference
derived
PubMed Identifier
30879358
Citation
Domenech M, Serra-Mir M, Roth I, Freitas-Simoes T, Valls-Pedret C, Cofan M, Lopez A, Sala-Vila A, Calvo C, Rajaram S, Sabate J, Ros E. Effect of a Walnut Diet on Office and 24-Hour Ambulatory Blood Pressure in Elderly Individuals. Hypertension. 2019 May;73(5):1049-1057. doi: 10.1161/HYPERTENSIONAHA.118.12766.
Results Reference
derived
PubMed Identifier
29478886
Citation
Freitas-Simoes TM, Cofan M, Blasco MA, Soberon N, Foronda M, Corella D, Asensio EM, Serra-Mir M, Roth I, Calvo C, Valls-Pedret C, Casaroli-Marano RP, Domenech M, Rajaram S, Sabate J, Ros E, Sala-Vila A. The red blood cell proportion of arachidonic acid relates to shorter leukocyte telomeres in Mediterranean elders: A secondary analysis of a randomized controlled trial. Clin Nutr. 2019 Apr;38(2):958-961. doi: 10.1016/j.clnu.2018.02.011. Epub 2018 Feb 17.
Results Reference
derived
PubMed Identifier
28119602
Citation
Rajaram S, Valls-Pedret C, Cofan M, Sabate J, Serra-Mir M, Perez-Heras AM, Arechiga A, Casaroli-Marano RP, Alforja S, Sala-Vila A, Domenech M, Roth I, Freitas-Simoes TM, Calvo C, Lopez-Illamola A, Haddad E, Bitok E, Kazzi N, Huey L, Fan J, Ros E. The Walnuts and Healthy Aging Study (WAHA): Protocol for a Nutritional Intervention Trial with Walnuts on Brain Aging. Front Aging Neurosci. 2017 Jan 10;8:333. doi: 10.3389/fnagi.2016.00333. eCollection 2016.
Results Reference
derived
PubMed Identifier
27636672
Citation
Fernandez-Cabello S, Valls-Pedret C, Schurz M, Vidal-Pineiro D, Sala-Llonch R, Bargallo N, Ros E, Bartres-Faz D. White matter hyperintensities and cognitive reserve during a working memory task: a functional magnetic resonance imaging study in cognitively normal older adults. Neurobiol Aging. 2016 Dec;48:23-33. doi: 10.1016/j.neurobiolaging.2016.08.008. Epub 2016 Aug 20.
Results Reference
derived
PubMed Identifier
27535872
Citation
Vaque-Alcazar L, Sala-Llonch R, Valls-Pedret C, Vidal-Pineiro D, Fernandez-Cabello S, Bargallo N, Ros E, Bartres-Faz D. Differential age-related gray and white matter impact mediates educational influence on elders' cognition. Brain Imaging Behav. 2017 Apr;11(2):318-332. doi: 10.1007/s11682-016-9584-8.
Results Reference
derived

Learn more about this trial

Walnuts and Healthy Aging

We'll reach out to this number within 24 hrs